Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sustained response with ixekizumab treatment of moderate-to-severe psoriasis with scalp involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Reich K, Leonardi C, Lebwohl M, Kerdel F, Okubo Y, Romiti R, Goldblum O, Dennehy EB, Kerr L, Sofen H. Reich K, et al. Among authors: goldblum o. J Dermatolog Treat. 2017 Jun;28(4):282-287. doi: 10.1080/09546634.2016.1249820. Epub 2016 Nov 13. J Dermatolog Treat. 2017. PMID: 27759463 Clinical Trial.
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. van de Kerkhof P, et al. Among authors: goldblum o. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27910156 Clinical Trial.
Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis.
Langley RGB, Reich K, Strand V, Feldman SR, Paul C, Gordon K, Warren RB, Toth D, Nikaï E, Zhu B, Goldblum O, Edson-Heredia E, Carlier H, Burge R, Lin CY, Hollister K, Augustin M. Langley RGB, et al. Among authors: goldblum o. Qual Life Res. 2020 Feb;29(2):369-380. doi: 10.1007/s11136-019-02296-5. Epub 2019 Oct 26. Qual Life Res. 2020. PMID: 31655974 Clinical Trial.
Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Kimball AB, et al. Among authors: goldblum o. J Am Acad Dermatol. 2016 Dec;75(6):1156-1161. doi: 10.1016/j.jaad.2016.07.034. Epub 2016 Sep 27. J Am Acad Dermatol. 2016. PMID: 27692498 Clinical Trial.
58 results